Oral bisphosphonate-related osteonecrosis of the jaw: Incidence, clinical features, prevention, and treatment recommendations

被引：4
作者：
Yarom N. [1 ,2 ,3 ]
Lazarovici T.S. [3 ]
Elad S. [4 ]
机构：
[1] Oral Medicine Clinic, Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Tel-Hashomer
[2] Department of Oral Pathology and Oral Medicine, Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv
[3] Department of Oral and Maxillofacial Surgery, Sheba Medical Center, Tel-Hashomer
[4] Department of Oral Medicine, Hebrew University, Hospital Oral Medicine Service, Jerusalem
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2010年 / 8卷 / 1期
关键词：
Alendronate; Bisphosphonates; Jaws; Osteonecrosis; Osteoporosis;
D O I：
10.1007/s12018-009-9055-5
中图分类号：
学科分类号：
摘要：
Biphosphonate-related osteonecrosis of the jaw (BRONJ) is a devastating side effect of oral bisphosphonates associated with patient morbidity and high financial burden to health services. BRONJ is usually associated with parenteral use of bisphosphonates in oncologic patients, but its incidence among individuals with osteoporosis who take oral bisphosphonates is on the rise. In the absence of definitive treatment for BRONJ, every effort should be made toward its prevention. The patients must be informed about the extremely small but proven risk of oral BRONJ and be recommended to undergo periodic dental evaluation and meticulous oral hygiene. Once BRONJ occurs, long-term antibiotic therapy and superficial curettage may be beneficial. © 2009 Humana Press Inc.
引用
收藏
页码：27 / 31
页数：4
相关论文
共 34 条
  • [1] Marx R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [1], Journal of Oral and Maxillofacial Surgery, 61, 9, pp. 1115-1117, (2003)
  • [2] Wang J., Goodger N.M., Pogrel M.A., Osteonecrosis of the jaws associated with cancer chemotherapy, Journal of Oral and Maxillofacial Surgery, 61, 9, pp. 1104-1107, (2003)
  • [3] Marx R.E., Sawatari Y., Fortin M., Broumand V., Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment, Journal of Oral and Maxillofacial Surgery, 63, 11, pp. 1567-1575, (2005)
  • [4] Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L., Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, Journal of Oral and Maxillofacial Surgery, 62, 5, pp. 527-534, (2004)
  • [5] Farrugia M.C., Summerlin D.-J., Krowiak E., Huntley T., Freeman S., Borrowdale R., Tomich C., Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates, Laryngoscope, 116, 1, pp. 115-120, (2006)
  • [6] Migliorati C.A., Schubert M.M., Peterson D.E., Seneda L.M., Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy, Cancer, 104, 1, pp. 83-93, (2005)
  • [7] Purcell P.M., Boyd I.W., Bisphosphonates and osteonecrosis of the jaw, Med J Aust, 182, pp. 417-418, (2005)
  • [8] Shlomi B., Levy Y., Kleinman S., Better H., Kahn A., Shtabsky A., Chaushu G., Avascular necrosis of the jaw bone after bisphosphonate therapy, Harefuah, 144, pp. 536-539, (2005)
  • [9] Marx R.E., Cillo Jr. J.E., Ulloa J.J., Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment, Journal of Oral and Maxillofacial Surgery, 65, 12, pp. 2397-2410, (2007)
  • [10] Brooks J.K., Gilson A.J., Sindler A.J., Ashman S.G., Schwartz K.G., Nikitakis N.G., Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 103, pp. 780-786, (2007)
1234